| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Non-cleavable Linker
DBCO-C6-acid does not have a specific biological target; it is a chemical tool for bioconjugation. The DBCO group reacts selectively with azide-functionalized molecules through strain-promoted alkyne-azide cycloaddition, which is bioorthogonal and does not require toxic copper catalysts. The C6 linker provides flexibility and spacing, reducing steric hindrance. |
|---|---|
| ln Vitro |
ADCs are made up of an antibody and an ADC cytotoxin that are joined together by an ADC linker.
In vitro, DBCO-C6-acid is used to modify azide-bearing proteins, polymers, or surfaces. It does not exert pharmacological activity but is utilized in labeling, imaging, and drug delivery systems. Its reactivity with azides is rapid and specific, with second-order rate constants typical of DBCO reagents (~0.1-1 M⁻¹s⁻¹). |
| ln Vivo |
No in vivo activity is attributed to DBCO-C6-acid itself, as it is a reactive intermediate. It may be used in vivo for pretargeted imaging or drug delivery if conjugated to a targeting moiety, but the compound alone is not administered as a therapeutic.
|
| Enzyme Assay |
As a chemical reagent, DBCO-C6-acid is not tested in cell-free receptor binding assays. Its reactivity is assessed by monitoring the formation of triazole adducts with azide-containing molecules using HPLC, LC-MS, or fluorescence if labeled. The reaction kinetics can be studied by UV-Vis spectroscopy.
|
| Cell Assay |
Cell-based assays typically involve incubation of DBCO-C6-acid with azide-modified cells or cell surfaces. For example, cells metabolically labeled with azide-sugars are treated with DBCO-C6-acid conjugated to a fluorophore or biotin. The efficiency of labeling is assessed by flow cytometry, fluorescence microscopy, or western blot. No cytotoxicity is observed at typical concentrations (≤100 µM).
|
| Animal Protocol |
In vivo animal experiments are not performed with DBCO-C6-acid alone. However, it may be used in pretargeting strategies where an azide-modified antibody is administered first, followed by a DBCO-labeled probe. The compound is typically administered intravenously, and its biodistribution is tracked via the conjugated label. No specific protocols exist for the free acid.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DBCO-C6-acid are not relevant as it is a reactive reagent. If administered, it would likely be rapidly cleared and metabolized. Its water solubility is moderate due to the hydrophobic DBCO group. The compound is stable at -20°C and should be handled under dry conditions.
|
| Toxicity/Toxicokinetics |
Toxicity data is not available for DBCO-C6-acid, but it is considered a low-toxicity reagent. It may cause skin and eye irritation. As a reactive compound, it should be handled with care. No genotoxicity or systemic toxicity data exists because it is not intended for in vivo use.
|
| References | |
| Additional Infomation |
DBCO-C6-acid is a bifunctional linker for click chemistry, with molecular formula C21H21NO3 and molecular weight 335.40. It is a white solid soluble in DMSO, DMF, and some organic solvents. It is commonly used for bioconjugation and surface modification. The compound is available from chemical suppliers for research use only and is not a drug.
|
| Molecular Formula |
C21H19NO3
|
|---|---|
| Molecular Weight |
333.380465745926
|
| Exact Mass |
333.136
|
| Elemental Analysis |
C, 75.66; H, 5.74; N, 4.20; O, 14.40
|
| CAS # |
1425485-72-8
|
| PubChem CID |
77078156
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
634.4±55.0 °C at 760 mmHg
|
| Flash Point |
337.5±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.654
|
| LogP |
4.48
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
558
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(CCCCC(=O)O)N1C2C=CC=CC=2C#CC2C=CC=CC=2C1
|
| InChi Key |
NIRLBCOFKPVQLM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H19NO3/c23-20(11-5-6-12-21(24)25)22-15-18-9-2-1-7-16(18)13-14-17-8-3-4-10-19(17)22/h1-4,7-10H,5-6,11-12,15H2,(H,24,25)
|
| Chemical Name |
6-(2-azatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaen-10-yn-2-yl)-6-oxohexanoic acid
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~299.96 mM）
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.50 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9996 mL | 14.9979 mL | 29.9958 mL | |
| 5 mM | 0.5999 mL | 2.9996 mL | 5.9992 mL | |
| 10 mM | 0.3000 mL | 1.4998 mL | 2.9996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
